Erratum: Enhanced antitumor effects of an engineered measles virus edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma (Molecular Therapy (2010) 18 (544-551) DOI:10.1038/mt.2009.296);Enhanced antitumor effects of an engineered measles virus edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma

Molecular Therapy

Volumn 18, Issue 3, 2010, Pages 544-551

  Meng, Xin ^a,b   Nakamura, Takafumi ^c,d   Okazaki, Toshihiko ^a   Inoue, Hiroyuki ^a   Takahashi, Atsushi ^a   Miyamoto, Shohei ^a   Sakaguchi, Gaku ^e   Eto, Masatoshi ^e   Naito, Seiji ^e   Takeda, Makoto ^f   Yanagi, Yusuke ^f   Tani, Kenzaburo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF TOKYO   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; ONCOLYTIC VIRUS; PROTEIN NPL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MEASLES VIRUS; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; SOLID TUMOR; TUMOR XENOGRAFT; VIRUS REPLICATION; VIRUS STRAIN; WESTERN BLOTTING; WILD TYPE;

MEASLES VIRUS; MUS MUSCULUS;

EID: 77649271463     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.56     Document Type: Erratum

References (44)

1. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540.
2. Kirn, DH and Thorne, SH (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9: 64-71.
3. Liu, TC and Kirn, D (2008). Gene therapy progress and prospects cancer: oncolytic viruses. Gene Ther 15: 877-884.
4. Aghi, M and Martuza, RL (2005). Oncolytic viral therapies-the clinical experience. Oncogene 24: 7802-7816.
5. Kim, M, Chung, YH and Johnston, RN (2007). Reovirus and tumor oncolysis. J Microbiol 45: 187-192.
6. Nettelbeck, DM, Rivera, AA, Balagué, C, Alemany, R and Curiel, DT (2002). Novel oncolytic adenoviruses targeted to melanoma: specifc viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 62: 4663-4670.
7. Connor, JH, Naczki, C, Koumenis, C and Lyles, DS (2004). Replication and cytopathic effect of oncolytic vesicular stomatitis virus in hypoxic tumor cells in vitro and in vivo. J Virol 78: 8960-8970.
8. Csatary, LK, Gosztonyi, G, Szeberenyi, J, Fabian, Z, Liszka, V, Bodey, B et al. (2004). MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67: 83-93.
9. Peng, KW, TenEyck, CJ, Galanis, E, Kalli, KR, Hartmann, LC and Russell, SJ (2002). Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 62: 4656-4662.
10. Fu, X, Tao, L and Zhang, X (2007). An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Ther 14: 480-487.
11. Heinzerling, L, Künzi, V, Oberholzer, PA, Kündig, T, Naim, H and Dummer, R (2005). Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells. Blood 106: 2287-2294.
12. Vidal, L, Pandha, HS, Yap, TA, White, CL, Twigger, K, Vile, RG et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137.
13. Haralambieva, I, Iankov, I, Hasegawa, K, Harvey, M, Russell, SJ and Peng, KW (2007). Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 15: 588-597.
14. Gauvrit, A, Brandler, S, Sapede-Peroz, C, Boisgerault, N, Tangy, F and Gregoire, M (2008). Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specifc CD8 response. Cancer Res 68: 4882-4892.
15. McDonald, CJ, Erlichman, C, Ingle, JN, Rosales, GA, Allen, C, Greiner, SM et al. (2006). A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. Breast Cancer Res Treat 99: 177-184.
16. Blechacz, B, Splinter, PL, Greiner, S, Myers, R, Peng, KW, Federspiel, MJ et al. (2006). Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44: 1465-1477.
17. Peng, KW, Ahmann, GJ, Pham, L, Greipp, PR, Cattaneo, R and Russell, SJ (2001). Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 98: 2002-2007.
18. Takeuchi, K, Kadota, SI, Takeda, M, Miyajima, N and Nagata, K (2003). Measles virus V protein blocks interferon (IFN)-cc/p but not IFN-y signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett 545: 177-182.
19. Dörig, RE, Marcil, A, Chopra, A and Richardson, CD (1993). The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75: 295-305.
20. Naniche, D, Varior-Krishnan, G, Cervoni, F, Wild, TF, Rossi, B, Rabourdin-Combe, C et al. (1993). Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 67: 6025-6032.
21. Tatsuo, H, Ono, N, Tanaka, K and Yanagi, Y (2000). SLAM (CDw150) is a cellular receptor for measles virus. Nature 406: 893-897.
22. Anderson, BD, Nakamura, T, Russell, SJ and Peng, KW (2004). High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res 64: 4919-4926.
23. Ong, HT, Timm, MM, Greipp, PR, Witzig, TE, Dispenzieri, A, Russell, SJ et al. (2006). Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 34: 713-720.
24. Naniche, D, Yeh, A, Eto, D, Manchester, M, Friedman, RM and Oldstone, MB (2000). Evasion of host defenses by measles virus: wild-type measles virus infection interferes with induction of cc/p interferon production. J Virol 74: 7478-7484.
25. Grandvaux, N, tenOever, BR, Servant, MJ and Hiscott, J (2002). The interferon antiviral response: from viral invasion to evasion. Curr Opin Infect Dis 15: 259-267.
26. Bourhis, JM, Canard, B and Longhi, S (2006). Structural disorder within the replicative complex of measles virus: functional implications. Virology 344: 94-110.
27. Hagiwara, K, Sato, H, Inoue, Y, Watanabe, A, Yoneda, M, Ikeda, F et al. (2008). Phosphorylation of measles virus nucleoprotein upregulates the transcriptional activity of minigenomic RNA. Proteomics 8: 1871-1879.
28. Dingli, D, Peng, KW, Harvey, ME, Greipp, PR, O'Connor, MK, Cattaneo, R et al. (2004). Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 103: 1641-1646.
29. Phuong, LK, Allen, C, Peng, KW, Giannini, C, Greiner, S, TenEyck, CJ et al. (2003). Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 63: 2462-2469.
30. Russell, SJ (2002). RNA viruses as virotherapy agents. Cancer Gene Ther 9: 961-966.
31. Ohno, S, Ono, N, Takeda, M, Takeuchi, K and Yanagi, Y (2004). Dissection of measles virus V protein in relation to its ability to block cc/p interferon signal transduction. J Gen Virol 85(Pt 10): 2991-2999.
32. Shingai, M, Ebihara, T, Begum, NA, Kato, A, Honma, T, Matsumoto, K et al. (2007). Differential type I IFN-inducing abilities of wild-type versus vaccine strains of measles virus. J Immunol 179: 6123-6133.
33. Haller, O, Kochs, G and Weber, F (2006). The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344: 119-130.
34. He, LF, Gu, JF, Tang, WH, Fan, JK, Wei, N, Zou, WG et al. (2008). Signifcant antitumor activity of oncolytic adenovirus expressing human interferon-β for hepatocellular carcinoma. J Gene Med 10: 983-992.
35. Ramachandran, A, Parisien, JP and Horvath, CM (2008). STAT2 is a primary target for measles virus V protein-mediated α/β interferon signaling inhibition. J Virol 82: 8330-8338.
36. Yokota, S, Saito, H, Kubota, T, Yokosawa, N, Amano, K and Fujii, N (2003). Measles virus suppresses interferon-α signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-α receptor complex. Virology 306: 135-146.
37. Takeda, M, Ohno, S, Tahara, M, Takeuchi, H, Shirogane, Y, Ohmura, H et al. (2008). Measles viruses possessing the polymerase protein genes of the Edmonston vaccine strain exhibit attenuated gene expression and growth in cultured cells and SLAM knock-in mice. J Virol 82: 11979-11984.
38. Bolt, G, Berg, K and Blixenkrone-Møller, M (2002). Measles virus-induced modulation of host-cell gene expression. J Gen Virol 83(Pt 5): 1157-1165.
39. Schneider-Schaulies, J, Dunster, LM, Schneider-Schaulies, S and ter Meulen, V (1995). Pathogenetic aspects of measles virus infections. Vet Microbiol 44: 113-125.
40. Niewiesk, S, Götzelmann, M and ter Meulen, V (2000). Selective in vivo suppression of T lymphocyte responses in experimental measles virus infection. Proc Natl Acad Sci USA 97: 4251-4255.
41. Yu, XL, Cheng, YM, Shi, BS, Qian, FX, Wang, FB, Liu, XN et al. (2008). Measles virus infection in adults induces production of IL-10 and is associated with increased CD4+ CD25+ regulatory T cells. J Immunol 181: 7356-7366.
42. Takeda, M, Takeuchi, K, Miyajima, N, Kobune, F, Ami, Y, Nagata, N et al. (2000). Recovery of pathogenic measles virus from cloned cDNA. J Virol 74: 6643-6647.
43. Tahara, M, Takeda, M and Yanagi, Y (2005). Contributions of matrix and large protein genes of the measles virus Edmonston strain to growth in cultured cells as revealed by recombinant viruses. J Virol 79: 15218-15225.
44. Radecke, F, Spielhofer, P, Schneider, H, Kaelin, K, Huber, M, Dötsch, C et al. (1995). Rescue of measles viruses from cloned DNA. EMBO J 14: 5773-5784.